Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Gastroenterology. 2012 Aug 1;143(5):1308–1318. doi: 10.1053/j.gastro.2012.07.109

Fig. 1.

Fig. 1

A. TTX, atropine, and darifenacin significantly attenuate the EFS-induced contraction of the rat colonic smooth muscle caused by EFS (*; p<0.05; n=6). SScIgG also causes significant (*; p<0.05; n=6) attenuation of these EFS responses that is reversed by pooledhIgG to values not significantly different from those obtained in the control and the pooledhIgG alone experiments (p>0.05). B. EFS causes a significant (*; p<0.05; n=4) increase in ACh release that is significantly (**; p<0.05; n=4) mitigated not only by 0Ca2+ and TTX but also by SScIgG. The effects of SScIgG are reversed by pooledhIgG pre-treatment. C. SScIgG significantly (*; p<0.05; n=6) inhibits M3-R activation-induced human SMC contraction by BeCh. These inhibitor effects of SScIgG are restored by pooledhIgG in a concentration-dependent manner (significantly by 1mg/ml pooledhIgG; *), and almost completely by 10 mg/ml pooledhIgG to the levels that are not significantly different from control, NIG and pooledhIgG experiments (p>0.05).